This finding is in line with Noda et al. [6], who demonstrated that high-risk MMP-14 expression—particularly at the tumor–stromal interface and in metastatic lymph nodes—is strongly associated with extranodal extension and poorer prognosis in OSCC patients. The gene discussed is MMP14; the disease is neoplasm.